Login / Signup

Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis and comorbid allergies.

Peter Schmid-GrendlmeierMelinda J GooderhamKarin HartmannKonstantinou GeorgeMarc FellmannChristopher KouliasClaire ClibbornPinaki BiswasPatrick M Brunner
Published in: Allergy (2023)
Efficacy and safety data support abrocitinib use to manage AD in patients with or without allergic comorbidities.
Keyphrases
  • atopic dermatitis
  • electronic health record
  • high intensity
  • early onset
  • big data
  • data analysis
  • allergic rhinitis